BMO Capital Markets Upgrades Eli Lilly and (LLY) to Market Perform

BMO Capital Markets upgraded shares of Eli Lilly and (NYSE:LLY) from an underperform rating to a market perform rating in a report published on Friday, Marketbeat reports. The firm currently has $79.00 price target on the stock, up from their previous price target of $74.00. The analysts noted that the move was a valuation call.

Several other equities analysts have also recently weighed in on LLY. Jefferies Group set a $90.00 price target on Eli Lilly and and gave the company a buy rating in a report on Friday. Zacks Investment Research raised Eli Lilly and from a hold rating to a buy rating and set a $87.00 price target on the stock in a report on Wednesday, April 11th. TheStreet cut Eli Lilly and from a b rating to a c rating in a report on Monday, March 5th. JPMorgan Chase set a $105.00 price target on Eli Lilly and and gave the company a buy rating in a report on Monday, February 26th. Finally, Credit Suisse Group reissued a hold rating and set a $80.00 price target on shares of Eli Lilly and in a report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $93.16.

How to Become a New Pot Stock Millionaire

Eli Lilly and stock opened at $80.12 on Friday. The company has a market capitalization of $87,341.06, a P/E ratio of 18.72, a P/E/G ratio of 1.49 and a beta of 0.26. Eli Lilly and has a twelve month low of $73.69 and a twelve month high of $89.09. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.06. The business had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.95 EPS. analysts expect that Eli Lilly and will post 4.87 EPS for the current fiscal year.

In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the sale, the insider now owns 4,130 shares in the company, valued at approximately $334,901.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Joshua L. Smiley sold 3,000 shares of the stock in a transaction on Friday, March 16th. The stock was sold at an average price of $79.20, for a total value of $237,600.00. Following the completion of the sale, the chief financial officer now owns 20,029 shares of the company’s stock, valued at approximately $1,586,296.80. The disclosure for this sale can be found here. Insiders sold a total of 15,261 shares of company stock valued at $1,225,085 in the last quarter. 0.11% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of LLY. Bank of Montreal Can grew its position in shares of Eli Lilly and by 85.4% during the fourth quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock valued at $391,156,000 after purchasing an additional 2,133,606 shares in the last quarter. Investec Asset Management LTD purchased a new position in Eli Lilly and in the fourth quarter worth about $163,570,000. Janus Henderson Group PLC grew its position in Eli Lilly and by 16.1% in the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after acquiring an additional 1,503,918 shares in the last quarter. Schroder Investment Management Group lifted its stake in Eli Lilly and by 81.3% in the fourth quarter. Schroder Investment Management Group now owns 2,300,675 shares of the company’s stock worth $194,315,000 after purchasing an additional 1,031,859 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its stake in Eli Lilly and by 110.9% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 1,832,626 shares of the company’s stock worth $154,783,000 after purchasing an additional 963,776 shares during the last quarter. Hedge funds and other institutional investors own 77.66% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was posted by Week Herald and is owned by of Week Herald. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://weekherald.com/2018/04/17/bmo-capital-markets-upgrades-eli-lilly-and-lly-to-market-perform.html.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply